Abstract
Elevated homocysteine (Hcy) levels are predictors of cardiovascular disease (CVD). Hyperhomocysteinemia has also been associated with total and CVD mortality. However, whether Hcy is just a marker or plays a causal role in CVD remains to be elucidated. In this narrative review, we discuss the associations between Hcy and non-cardiac vascular diseases, namely stroke, peripheral artery disease (PAD), carotid artery disease, chronic kidney disease (CKD), atherosclerotic renal artery stenosis (ARAS), abdominal aortic aneurysm (AAA) and erectile dysfunction (ED). The effects of several drugs on Hcy levels are also considered.
Folic acid, vitamin B6 and B12 supplementation can significantly decrease circulating Hcy concentrations but their effects on CVD risk reduction are conflicting. No current guidelines recommend the routine screening of Hcy levels in patients with non-cardiac vascular diseases. Therefore, further research is needed to elucidate the use of Hcy in the clinical practice.Keywords: Homocysteine, stroke, peripheral artery disease, carotid artery disease, chronic kidney disease, erectile dysfunction, vitamin B.
Current Pharmaceutical Design
Title:Homocysteine and Non-Cardiac Vascular Disease
Volume: 23 Issue: 22
Author(s): Niki Katsiki, Pablo Perez-Martinez and Dimitri P. Mikhailidis*
Affiliation:
- Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College London (UCL), Pond Street, London NW3 2QG,United Kingdom
Keywords: Homocysteine, stroke, peripheral artery disease, carotid artery disease, chronic kidney disease, erectile dysfunction, vitamin B.
Abstract: Elevated homocysteine (Hcy) levels are predictors of cardiovascular disease (CVD). Hyperhomocysteinemia has also been associated with total and CVD mortality. However, whether Hcy is just a marker or plays a causal role in CVD remains to be elucidated. In this narrative review, we discuss the associations between Hcy and non-cardiac vascular diseases, namely stroke, peripheral artery disease (PAD), carotid artery disease, chronic kidney disease (CKD), atherosclerotic renal artery stenosis (ARAS), abdominal aortic aneurysm (AAA) and erectile dysfunction (ED). The effects of several drugs on Hcy levels are also considered.
Folic acid, vitamin B6 and B12 supplementation can significantly decrease circulating Hcy concentrations but their effects on CVD risk reduction are conflicting. No current guidelines recommend the routine screening of Hcy levels in patients with non-cardiac vascular diseases. Therefore, further research is needed to elucidate the use of Hcy in the clinical practice.Export Options
About this article
Cite this article as:
Katsiki Niki , Perez-Martinez Pablo and Mikhailidis P. Dimitri *, Homocysteine and Non-Cardiac Vascular Disease, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170317124913
DOI https://dx.doi.org/10.2174/1381612823666170317124913 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Multi-scale LBP and SVM Classification to Identify Diabetic Retinopathy in Lesions
Current Medical Imaging Structural Development, Haematological Immunological and Pharmacological Effects of Quinolones
Recent Patents on Anti-Infective Drug Discovery Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Current Drug Targets The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Hemodialysis Membranes for Acute and Chronic Renal Insufficiency
Current Neurovascular Research Measurement of Cerebral Blood Flow with Near Infrared Spectroscopy and Indocyanine Green Dye Dilution
Current Medical Imaging Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Clinical Characteristics of Behcet’s Disease in 453 Egyptian Patients Suffering from Uveitis with Gender Comparison
Current Rheumatology Reviews Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Endothelial Progenitor Cells (EPCs) Evaluation in Aortic Aneurysm Repair
Current Vascular Pharmacology Perioperative Handling of Antiplatelet Drugs. A Critical Appraisal
Current Drug Targets Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Ultrasonographic Assessment of Cirrhosis and Portal Hypertension
Current Medical Imaging Early Timing of Endovascular Treatment for Aneurysmal Subarachnoid Hemorrhage Achieves Improved Outcomes
Current Neurovascular Research Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews